Drug Profile
Research programme: anticancer therapeutics - Chroma Therapeutics/Infinity Pharmaceuticals
Latest Information Update: 15 May 2008
Price :
$50
*
At a glance
- Originator Chroma Therapeutics; Infinity Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
- 05 Apr 2005 Preclinical trials in Cancer in USA (unspecified route)